$再生元制药(REGN)$ The sales momentum of Bayer and Regeneon's eye drug Eylea has slowed considerably in the second half of 2022. Bayer said on Tuesday that it will continue until a new 8 mg formulation of the drug is approved.
| 发布于: | 雪球 | 转发：0 | 回复：0 | 喜欢：0 |
$再生元制药(REGN)$ The sales momentum of Bayer and Regeneon's eye drug Eylea has slowed considerably in the second half of 2022. Bayer said on Tuesday that it will continue until a new 8 mg formulation of the drug is approved.